디지털 PCR 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of digital PCR Market

The global digital PCR market is experiencing rapid expansion due to rising demand for high-precision molecular diagnostics, increasing prevalence of infectious and genetic diseases, and continuous technological advancements. The market was valued at USD 857.2 million in 2025 and is projected to grow to USD 1,043.20 million in 2026. It is expected to reach USD 5,776.73 million by 2034, registering a strong CAGR of 23.90% during 2026-2034.

North America dominated the global market with a 43.70% market share in 2025, supported by early adoption of advanced molecular diagnostic technologies and strong biopharmaceutical research infrastructure.

Market Overview

Digital Polymerase Chain Reaction (dPCR) is an advanced form of conventional PCR technology that enables absolute quantification of nucleic acids (DNA/RNA). It offers enhanced sensitivity, precision, and reproducibility compared to real-time PCR. Key advantages include high throughput capability, improved detection accuracy, cost-effectiveness, and faster processing.

Rising cases of infectious diseases, cancer, and genetic disorders are major drivers of the digital PCR market. Increased acquisitions, product launches, and expansion of laboratory adoption further support industry growth. Technological advancements in digital platforms are also contributing significantly to market expansion.

COVID-19 Impact

The COVID-19 pandemic positively impacted the digital PCR market. In 2020, the market recorded a substantial growth rate of 38.6%, compared to 18.1% in 2019, driven by massive global demand for accurate COVID-19 diagnostics.

The surge in testing volumes led to increased adoption of digital PCR devices in clinical laboratories and research institutes. Although post-pandemic decline in COVID-19 cases reduced testing volumes, the resumption of routine diagnostics in 2021 and growing applications in oncology and genetic testing sustained strong demand. Continuous innovation in dPCR assays and equipment for biopharmaceutical applications further strengthened market momentum heading into the 2025-2034 forecast period.

Digital PCR Market Trends

Shift from Droplet to Chip-Based Digital PCR

A notable trend in the market is the gradual shift from droplet-based digital PCR (ddPCR) to chip-based systems. While droplet systems dominate currently, chip-based technologies reduce risks of cross-contamination and improve workflow efficiency. Chip-based tests offer advantages such as faster processing, simplicity, and cost-effectiveness.

Increasing incidence of infectious diseases and growing cancer burden are accelerating adoption of advanced chip-based digital PCR technologies. This shift is expected to further drive the digital PCR market growth during the forecast period.

Market Growth Drivers

Technological Advancements

Continuous innovation in digital PCR systems-including droplet, chip-based, beam, and crystal reaction techniques-has significantly enhanced performance and application scope. Market players are launching fully automated integrated systems to support both research and in vitro diagnostic applications.

Increased R&D investments by public and private organizations are accelerating development of next-generation dPCR platforms, expanding their use in oncology, infectious disease testing, and genetic mutation analysis.

Advantages Over Real-Time PCR

Digital PCR offers absolute quantification without reliance on standard curves, delivering higher sensitivity and precision. It is particularly effective in detecting low viral loads and minor genetic variations. These advantages make it highly suitable for applications such as cancer mutation detection and infectious disease diagnosis.

Growing preference for digital PCR over traditional real-time PCR is expected to drive strong adoption globally.

Restraining Factors

Despite strong growth prospects, certain challenges may limit expansion:

• High cost of digital PCR instruments
• Requirement for skilled professionals
• Competition from alternative technologies such as Next-Generation Sequencing (NGS)
• Limited availability of microfluidic consumables in low-income regions

These factors may slow adoption in developing economies.

Market Segmentation Analysis

By Type

The market is segmented into:

• Droplet Digital PCR
• Chip-Based Digital PCR
• Others

The droplet dPCR segment dominated with a 82.04% market share in 2026, driven by increasing product launches and widespread use in infectious disease diagnostics. However, chip-based systems are projected to grow steadily due to workflow efficiency and contamination control advantages.

By Product

• Instruments
• Reagents & Consumables

The instruments segment accounted for 59.01% market share in 2026, supported by rising product launches and advanced system integration.

The reagents & consumables segment is expected to grow at the highest CAGR, fueled by increasing commercialization of diagnostic kits and expanding research applications.

By Indication

• Infectious Diseases
• Oncology
• Genetic Disorders
• Others

The genetic disorders segment dominated with 51.56% share in 2026, driven by high sensitivity in detecting gene mutations.

The oncology segment is projected to grow at a substantial CAGR due to increasing cancer prevalence. The infectious diseases segment is expected to register the highest CAGR owing to the clinically proven effectiveness of digital PCR in viral and bacterial detection.

By End User

• Academic & Research Organizations
• Clinical Laboratories
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies

The academic & research organizations segment led the market with 67.90% share in 2026, reflecting extensive use in research studies.

The clinical laboratories segment is expected to expand at the highest CAGR due to growing infectious disease testing volumes.

Regional Insights

North America

North America generated USD 374.68 million in 2025, maintaining dominance in the global market. The U.S. market is projected to reach USD 426.29 million in 2026. Strong research funding and high technology adoption drive regional growth.

Europe

Europe is projected to grow at a moderate CAGR, supported by increasing R&D investments and government initiatives. Germany is expected to reach USD 82.64 million in 2026, while the UK is projected at USD 33.09 million in 2026.

Asia Pacific

Asia Pacific is expected to grow at the highest CAGR during the forecast period.

• Japan market projected at USD 50.98 million in 2026
• China market projected at USD 83.81 million in 2026
• India market projected at USD 30.93 million in 2026

Growth is driven by improving healthcare infrastructure and high disease burden.

Latin America & Middle East & Africa

These regions are projected to witness significant growth due to improving healthcare infrastructure and increasing clinical research activities.

Competitive Landscape

The digital PCR market is consolidated, with leading players including:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN
• Stilla
• Sysmex Corporation
• Standard BioTools Inc.
• JN Medsys

Bio-Rad Laboratories holds a dominant position due to its strong droplet digital PCR portfolio and strategic acquisitions. Partnerships, product launches, and geographic expansion strategies are strengthening the competitive landscape.

Conclusion

The global digital PCR market is poised for remarkable growth from USD 857.2 million in 2025 to USD 5,776.73 million by 2034, driven by rising infectious and genetic disease prevalence, technological advancements, and expanding research applications. With a projected CAGR of 23.90% from 2026-2034, the market is expected to witness substantial expansion, particularly across North America and Asia Pacific, positioning digital PCR as a critical technology in the future of molecular diagnostics.

Growth Rate CAGR of 23.90% from 2026-2034

Segmentation

By Type

• Droplet Digital PCR
• Chip-based Digital PCR
• Others

By Product

• Instruments
• Reagents & Consumables

By Indication

• Infectious Diseases
• Oncology
• Genetic Disorders
• Others

By End-user

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Industries
• Clinical Laboratories
• Academic & Research Organizations

By Geography

• North America (By Type, Product, By Indication, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, By Indication, End-user, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Chronic Diseases (Cancer and Infectious Disease), By Key Countries/Regions, 2025
• 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• 4.3. Regulatory Scenario, By Key Countries/Region
• 4.4. Technological Advancements in Digital PCR
• 4.5. Impact of Covid-19 on the Market

5. Global Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Droplet Digital PCR
  • 5.1.2. Chip-based Digital PCR
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Instruments
  • 5.2.2. Reagents & Consumables
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Infectious Diseases
  • 5.3.2. Oncology
  • 5.3.3. Genetic Disorders
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End-user
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Pharmaceutical & Biotechnology Industries
  • 5.4.3. Clinical Laboratories
  • 5.4.4. Academic & Research Organisations
• 5.5. Market Analysis, Insights and Forecast - By Geography
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Droplet Digital PCR
  • 6.1.2. Chip-based Digital PCR
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Instruments
  • 6.2.2. Reagents & Consumables
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Infectious Diseases
  • 6.3.2. Oncology
  • 6.3.3. Genetic Disorders
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End-user
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Pharmaceutical & Biotechnology Industries
  • 6.4.3. Clinical Laboratories
  • 6.4.4. Academic & Research Organisations
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Droplet Digital PCR
  • 7.1.2. Chip-based Digital PCR
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Instruments
  • 7.2.2. Reagents & Consumables
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Infectious Diseases
  • 7.3.2. Oncology
  • 7.3.3. Genetic Disorders
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End-user
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Pharmaceutical & Biotechnology Industries
  • 7.4.3. Clinical Laboratories
  • 7.4.4. Academic & Research Organisations
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Droplet Digital PCR
  • 8.1.2. Chip-based Digital PCR
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Instruments
  • 8.2.2. Reagents & Consumables
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Infectious Diseases
  • 8.3.2. Oncology
  • 8.3.3. Genetic Disorders
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End-user
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Pharmaceutical & Biotechnology Industries
  • 8.4.3. Clinical Laboratories
  • 8.4.4. Academic & Research Organisations
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of APAC

9. Latin America Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Droplet Digital PCR
  • 9.1.2. Chip-based Digital PCR
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Instruments
  • 9.2.2. Reagents & Consumables
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Infectious Diseases
  • 9.3.2. Oncology
  • 9.3.3. Genetic Disorders
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End-user
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Pharmaceutical & Biotechnology Industries
  • 9.4.3. Clinical Laboratories
  • 9.4.4. Academic & Research Organisations
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Droplet Digital PCR
  • 10.1.2. Chip-based Digital PCR
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Instruments
  • 10.2.2. Reagents & Consumables
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Infectious Diseases
  • 10.3.2. Oncology
  • 10.3.3. Genetic Disorders
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By End-user
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Pharmaceutical & Biotechnology Industries
  • 10.4.3. Clinical Laboratories
  • 10.4.4. Academic & Research Organisations
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. QIAGEN
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (based on availability)
  • 11.2.2. Thermo Fisher Scientific Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (based on availability)
  • 11.2.3. Bio-Rad Laboratories, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (based on availability)
  • 11.2.4. JN Medsys
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (based on availability)
  • 11.2.5. Stilla
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (based on availability)
  • 11.2.6. Sysmex Corporation
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (based on availability)
  • 11.2.7. Standard BioTools Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (based on availability)
  • 11.2.8. Precigenome LLC.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (based on availability)